Calcineurin inhibitors are immunosuppressant drugs that help prevent rejection of transplanted organs. They work by blocking the action of calcineurin, a protein that immune cells need to multiply and respond to antigens. This helps suppress the immune system and prevents rejection of transplanted organs like kidneys, heart, liver and lungs.
The global Calcineurin Inhibitor Market is estimated to be valued at US$ 10.07 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the calcineurin inhibitor market is the introduction of generic versions and biosimilars. When patents for branded drugs expire, generic drug manufacturers introduce low-cost versions to gain market share. For example, in 2021, Mylan launched generic versions of cyclosporine capsules and tacrolimus capsules in the US after patents expired for branded versions Neoral and Prograf. This increased treatment access and reduced costs. However, it also intensified competition and pricing pressures for innovators.
Strength: Calcineurin inhibitors such as cyclosporine and tacrolimus are well-established and effective drugs for preventing transplant rejection with decades of clinical history. They act by inhibiting calcineurin, which is crucial for T-cell activation and survival.
Weakness: Long-term use of calcineurin inhibitors can cause undesirable side effects like nephrotoxicity, hypertension, diabetes, and increased risk of infection and cancer. Their use is also associated with organ toxicity.
Opportunity: Growing organ transplantation procedures worldwide due to the increasing prevalence of organ failure presents an opportunity for calcineurin inhibitor drugs. Development of safer and more targeted molecules can further expand the market.
Threats: Availability of alternative immunosuppressants and transplant approaches pose competition. Strict regulations for drug approval can delay market entry of new products. Additionally, high development costs of new drugs is a challenge.
The global calcineurin inhibitor market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing number of organ transplantation surgeries worldwide.
Regional analysis: North America dominates the global market and is expected to continue its dominance in the coming years. However, Asia Pacific is anticipated to be the fastest-growing regional market due to growing healthcare infrastructure, rising medical tourism, and increasing expenditure on healthcare in several APAC countries.
Key players operating in the Calcineurin Inhibitor market are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it